Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

34 results about "Antiprotozoal Agent" patented technology

A pharmacological agent that can kill or prevent the reproduction of parasitic protozoans.

Betulin derived compounds useful as antiprotozoal agents

The invention relates to betulin derivatives, and to the use thereof as agents against protozoa of the genus Leishmania and against leishmaniasis in applications of pharmaceutical industry.
Owner:VALTION TEKNILLINEN TUTKIMUSKESKUS

Novel Dihydroxybenzene Derivatives and Antiprotozoal Agent Comprising Same as Active Ingredient

Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I)(wherein, X represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; R2 represents a hydrogen atom or a C1-7 alkyl group; R3 represents —CHO, —C(═O)R5, —COOR5 (wherein R5 represents a C1-7 alkyl group), —CH2OH or —COOH; and R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and / or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and / or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and / or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.
Owner:NAI

Addition salts of azithromycin and citric acid and process for preparing them

Said addition salts have a molar ratio between azithromycin and citric acid such as to provide a pH comprised between 4.0 and 8.0 in a 10% aqueous solution. The process for preparing said salts comprises: a) dissolving azithromycin in a solvent or mixture of solvents; b) adding citric acid; and c) isolating the product obtained by crystallisation. The addition salts of azithromycin and citric acid are stable and soluble in aqueous medium, being useful antibacterial and antiprotozoan agents.
Owner:QUIMICA SINTETICA

Anticancer and antiprotozoal dihydroartemisinene and dihydroartemisitene dimers with desirable chemical functionalities

This invention comprises compositions containing dihydroartemisinin- and dihydroartemisitene-dimers with activity as anticancer or anticancer metastasis agents and anti-protozal, including anti-malarial and anti-leishmanial properties. This invention also describes methods of preparation of these compositions and methods of use of such compositions for the treatment of cancer or prevention of cancer metastasis, and protozoal infections, including malaria, or leishmaniasis. The compounds of this invention represent a potential new class of anti-tumor or anti-metastasis agents, one that has shown promising activity against solid tumors.
Owner:ELSOHLY LAB

Boron containing small molecules as antiprotozoal agents

This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent. The exemplary compounds have the following formula:wherein X is selected from the group consisting of substituted phenyl, substituted or unsubstituted heteroaryl and unsubstituted cycloalkyl; R3a is selected from the group consisting of H, unsubstituted C1 or C2 or C3 or C4 or C5 or C6 alkyl and unsubstituted C3 or C4 or C5 or C6 cycloalkyl; R3b is selected from the group consisting of H, unsubstituted C1 or C2 or C3 or C4 or C5 or C6 alkyl and unsubstituted C3 or C4 or C5 or C6 cycloalkyl;with the proviso that R3a and R3b, along with the atom to which they are attached, are optionally joined to form a 3 or 4 or 5 or 6 membered ring, with the proviso that R3a and R3b cannot both be H, or a salt thereof.
Owner:ANACOR PHARMA INC

Dihydroxybenzene derivatives and antiprotozoal agent comprising same as active ingredient

Novel compounds below are useful for preventing or treating diseases caused by protozoans. At least one of a compound represented by Formula (I)(wherein, X represents a hydrogen atom or a halogen atom; R1 represents a hydrogen atom; R2 represents a hydrogen atom or a C1-7 alkyl group; R3 represents —CHO, —C(═O)R5, —COOR5 (wherein R5 represents a C1-7 alkyl group), —CH2OH or —COOH; and R4 represents a C1-16 alkyl group having one or more substituents on a terminal carbon atom and / or non-terminal carbon atom(s), a C2-16 alkenyl group having one or more substituents on a terminal carbon atom and / or non-terminal carbon atom(s), or a C2-16 alkynyl group having one or more substituents on a terminal carbon atom and / or non-terminal carbon atom(s)), an optical isomer thereof, and a pharmaceutically acceptable salt is used.
Owner:NAI

Coccidian Parasite Casein Kinase I as a Chemotherapeutic Target for Antiprotozoal Agents

Isolated nucleic acid molecules encoding coccidian casein kinase I, CKI, enzymes from the species Eimeria tenella and Toxoplasma gondii are disclosed. The isolation of these coccidian CKI cDNA sequences results in the disclosure of purified forms of E. tenella and T. gondii CKI proteins, recombinant vectors and recombinant hosts which express coccidian CKI.
Owner:MERCK SHARP & DOHME CORP

N-formyl hydroxylamine derivatives as inhibitors of bacterial polypeptide formylase for treating microbial infections

Compounds of formula (I) are antibacterial or antiprotozoal agents for treatment of infections in humans and non-human mammals, wherein: Z represents a radical of formula —N(OH)CH(═O) or formula C(═O)NH(OH); R1 represents hydrogen, methyl or trifluromethyl, or except when Z is a radical of formula —N(OH)(═O), a hydroxy, halo or amino group; R2 represents a group R10—(X)n-(ALK)m— wherein R10, ALK, X, m and n are as defined in the specification; R3 represents hydrogen, (C1–C6) alkyl or phenyl(C1–C6)alkyl-; and R5 and R6 are as defined in the specification.
Owner:BRITISH BIOTECH PHARMA LTD

Anticancer and Antiprotozoal Dihydroartemisinene and Dihydroartemisitene Dimers with Desirable Chemical Functionalities

This invention comprises compositions containing dihydroartemisinin- and dihydroartemisitene-dimers with activity as anticancer or anticancer metastasis agents and anti-protozal, including anti-malarial and anti-leishmanial properties. This invention also describes methods of preparation of these compositions and methods of use of such compositions for the treatment of cancer or prevention of cancer metastasis, and protozoal infections, including malaria, or leishmaniasis. The compounds of this invention represent a potential new class of anti-tumor or anti-metastasis agents, one that has shown promising activity against solid tumors.
Owner:ELSOHLY LAB

Antiprotozoal imidazopyridine compounds

ActiveUS7429590B2BiocideOrganic chemistryDiseaseProtozoal diseases
Compounds described by the Formula (I) or (II): or pharmaceutically acceptable salts, or N-oxides thereof. The compounds are useful for the treatment and prevention of protozoal diseases in mammals and birds. A method for controlling coccidiosis in poultry comprises administering an effective amount of the compound alone, or in combination with one or more anticoccidieal agent(s). A composition for controlling coccidiosis in poultry comprises the compound alone, or in combination with one or more anticoccidial agent(s). Methods for the treatment and prevention of mammalian protozoal diseases, such as, for example, toxoplasmosis, malaria. African typanosomiasis, Chagas disease, and opportunistic infections comprise administering the compound alone, or in combination with one or more antiprotozoal agent(s).
Owner:MERCK SHARP & DOHME LLC

Dna encoding novel cyclic gmp dependent protein kinases from two protozoal sources for use as chemotherapeutic targets for antiprotozoal agents

The present invention relates to novel protozoal cyclic GMP dependent protein kinases and genes encoding same that have been isolated from Eimeria maxima and Plasmodium falciparum. Nucleic acid molecules having sequences that encode such proteins as well as antibodies raised against such proteins are also disclosed. These enzymes may be used in screening assays to identify potential antiprotozoal agents. As well, methods to obtain such nucleic acid molecules, proteins, antibodies and inhibitor are also provided as are therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and inhibitors as well as their use to protect animals from disease caused by parasites such as Eimeria maxima and Plasmodium falciparum.
Owner:MERIAL INC

Antiprotozoal agent

An antiprotozoal agent effective especially as an antileishmania agent. The antiprotozoal agent contains as an active ingredient a compound represented by the formula (I): [Chemical formula 1] (I) (wherein R represents -H or acyl), a salt of the compound, or a solvate of either.
Owner:HEALTH SCI TECH TRANSFER CENT JAPAN HEALTH SCI FOUND

Antiprotozoal imidazopyridine compounds

Compounds described by the Formula (I): (I) or pharmaceutically acceptable salts, or N-oxides thereof. The compounds are useful for the treatment and prevention of protozoal diseases in mammals and birds. A method for controlling coccidiosis in poultry comprises administering an effective amount of the compound alone, or in combination with one or more anticoccidial agent(s). A composition for controlling coccidiosis in poultry comprises the compound alone, or in combination with one or more anticoccidial agent(s). Methods for the treatment and prevention of mammalian protozoal diseases, such as, for example, toxoplasmosis, malaria, African trypanosomiasis, Chagas disease, and opportunistic infections comprise administering the compound alone, or in combination with one or more antiprotozoal agent(s).
Owner:MERIAL INC

internal parasite control agent

In order to provide a new parasite control agent such as anthelmintic or antiprotozoal, which has an effective control effect on animal endoparasites that cannot be controlled by conventional anthelmintics or antiprotozoal agents, the present invention provides a general formula An endoparasite control agent in which the heterocyclic carboxamide derivative or its salt shown in (I) is an active ingredient.
Owner:THE UNIV OF TOKYO +1

Cyclic GMP dependent protein kinase as a chemotherapeutic target for antiprotozoal agents

Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.
Owner:MERIAL INC

Nucleic acids encoding novel cyclic GMP dependent protein kinases from Elmeria maxima

The present invention relates to novel protozoal cyclic GMP dependent protein kinases and genes encoding same that have been isolated from Eimeria maxima and Plasmodium falciparum. Nucleic acid molecules having sequences that encode such proteins as well as antibodies raised against such proteins are also disclosed. These enzymes may be used in screening assays to identify potential antiprotozoal agents. As well, methods to obtain such nucleic acid molecules, proteins, antibodies and inhibitor are also provided as are therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies and inhibitors as well as their use to protect animals from disease caused by parasites such as Eimeria maxima and Plasmodium falciparum.
Owner:MERIAL INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products